Bayside Biosciences

Executive Summary

Bayside Biosciences is a preclinical contract research organization (CRO) headquartered in San Diego, California, providing comprehensive drug development services to biotech and pharmaceutical companies. Founded in 2019, the company specializes in bioanalytical assays, molecular and cell biology, and in vitro/in vivo pharmacology studies. It supports a wide range of therapeutic modalities including antibodies, small molecules, siRNAs, proteins, and gene therapies. As a service provider, Bayside enables its clients to advance drug candidates through preclinical stages without the capital intensity of in-house facilities. The company's business model is fee-for-service, with revenue tied to project volume and client retention. The preclinical CRO market is fragmented but growing, driven by outsourcing trends in biopharma R&D. Bayside's competitive advantages include its early-stage focus, broad modality coverage, and location in a major biotech hub. While the company is privately held and does not disclose financials, its steady presence in the industry suggests a stable revenue base and potential for growth as its client base expands.

Upcoming Catalysts (preview)

• Q1 2026New Service Offering Launch (e.g., in vivo imaging or exosome characterization)70% success
• Q2 2026Major Partnership with a Top 10 Pharma Company40% success
• Q3 2026Expansion into New Lab Facility or Geographic Location60% success